Therapeutic Anticoagulation May Be Associated with Reduced 14-day Mortality in Mechanically Ventilated Patients with COVID-19

Randi Jenkins, PharmD1; Sahil Sheth, PharmD, BCCCP2; Breanne Nestor, PharmD, BCCCP1; Adrien Mazer, MD2
1Department of Pharmacy Services, Anne Arundel Medical Center, Annapolis, Maryland
2Department of Critical Care Medicine, Anne Arundel Medical Center, Annapolis, Maryland

Abstract

**Purpose:** To assess the impact of therapeutic dose versus prophylactic dose anticoagulation regimens on outcomes in mechanically ventilated patients with COVID-19.

**Methods:** We performed a retrospective cohort analysis of consecutive mechanically ventilated adult patients with COVID-19 admitted to the intensive care unit (ICU) and initiated on anticoagulation from February 1st to May 31st, 2020. The primary endpoint was 14-day mortality. Secondary endpoints included 30-day mortality, hospital length of stay (LOS), duration of mechanical ventilation, major bleeding, and new thromboembolic event.

**Results:** Of the 121 mechanically ventilated patients with COVID-19, 33 in the therapeutic-dose group and 34 patients in the prophylactic-dose group were included in the final analysis. The therapeutic-dose group had a decreased 14-day mortality compared to the prophylaxis dose group (9.1% vs 41.2%, p=0.004). In addition, 30-day mortality was also lower in the therapeutic anticoagulation group (24.2% vs. 52.9%, p=0.024). A longer hospital LOS (45.7 vs 26 days, p=0.003) and duration of mechanical ventilation (33.9 vs 13.3 days, p<0.001) were observed in patients on therapeutic anticoagulation in comparison to the prophylaxis dosing group. A higher rate of major bleeding was observed in patients who received therapeutic anticoagulation.

**Conclusion:** In this analysis of mechanically ventilated COVID-19 patients in the ICU, therapeutic dose anticoagulation was associated with a significantly lower 14-day mortality, but increased bleeding.

**Keywords:** anticoagulation, COVID-19, critical care, mechanical ventilation, venous thromboembolism

---

**Introduction**

SARS-CoV-2 is a respiratory infectious disease that has caused a global pandemic with high rates of morbidity and mortality. Severe presentation of the disease is characterized by a wide array of clinical manifestations such as acute respiratory distress syndrome (ARDS), acute kidney injury, neurologic sequelae and coagulopathy characterized by elevated levels of fibrinogen and D-dimer. Specifically, increased levels of prothrombotic coagulation parameters have been associated with more severe disease and an increased mortality in hospitalized patients. Microthrombi discovered during autopsies of COVID-19 patients are hypothesized to play a large role in the pathogenesis of the disease. Observational studies have found a thromboembolic incidence of up to 31% among patients in the ICU admitted with COVID-19. Reported mortality rates have ranged from 36% to 88% in those requiring intubation. Consequently, institutions established several prophylactic and therapeutic anticoagulation dosing protocols/recommendations in an effort to reduce thromboembolic events and associated morbidity and mortality.

Current guidance and recommendations published by organizations such as National Institutes of Health (NIH), World Health Organization (WHO) and International Society on Thrombosis and Hemostasis (ISTH) recommend either prophylactic or intermediate-dose prophylactic anticoagulation in critically ill patients with COVID-19. However, observational reports suggest using therapeutic anticoagulation in high risk patients or those admitted with elevated D-dimers. A recent study demonstrated improvements in 21-day survival of mechanically ventilated patients who received therapeutics doses of anticoagulation. In this study, we assessed the impact of therapeutic dose versus prophylactic dose anticoagulation on 14-day mortality in mechanically ventilated patients with COVID-19.

**Methods**

**Patients.** This was a retrospective single-center study conducted at a 389-bed community teaching hospital in Maryland. The institution has 28 ICU beds and utilizes EPIC electronic medical record (EMR) system. All mechanically ventilated adult patients with COVID-19 admitted to the ICU who received unfractionated heparin or low molecular weight heparin between February 1st 2020 and May 31st 2020 were evaluated for inclusion. COVID-19 positivity was defined as a laboratory confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay in any specimen. Patients on less than 72 hours of mechanical ventilation, receiving anticoagulation prior to admission or transferred from (or to) another acute care facility...
outside of the health system were excluded from the study. Additional exclusion criteria included patients who were pregnant or in the peripartum period and those receiving anticoagulation for indications other than COVID-19. The institutional Clinical Research Committee reviewed this study protocol (IRBNet ID 1618531-1) in June 2020 and deemed it to be IRB exempt.

Data Collection. Demographic and baseline data collected using EMR included patient age, sex, body mass index (BMI), Acute Physiology and Chronic Health Evaluation (APACHE) II Score, Charlson Comorbidity Index, D-dimer, PaO2/FiO2 ratio, fibrinogen, C-reactive protein (CRP) and ferritin. All baseline demographic and laboratory data was recorded upon ICU admission. Clinical data collected included anticoagulant type, anticoagulant dosing regimen, 14-day mortality, 30-day mortality, hospital LOS, duration of mechanical ventilation, major bleeding and new thromboembolic event. Other data collection points included rate of crossover between groups, protocol compliance and receipt of other COVID-19 therapies. Anticoagulation dosing regimen was initiated and/or continued at the discretion of the attending provider in addition to a prophylaxis with unfractionated heparin (UFH) or enoxaparin. Patients who received either standard or intermediate dose thromboprophylaxis were included in the final analysis. 33 patients in the therapeutic dose group and 34 patients in the prophylaxis dose group were included in the final analysis (Figure 1).

Study Groups. Prophylactic anticoagulation group consisted of patients who received either standard or intermediate dose prophylaxis with unfractionated heparin (UFH) or enoxaparin. Standard dose thromboprophylaxis was defined as UFH dosed at 5000 units subcutaneously every 8 to 12 hours or enoxaparin dosed at 40 or 30 milligram (mg) subcutaneously daily per patient’s renal function. Intermediate dose thromboprophylaxis was defined as patients receiving unfractionated heparin dosed at 7500 units every 8 hours or enoxaparin dosed at 40 mg every 12 hours per patient’s renal function.

Therapeutic anticoagulation group consisted of patients who received an intravenous (IV) UFH infusion with target activated partial thromboplastin time (aPTT) of 55 to 77 seconds or enoxaparin dosed at 1 mg per kilogram (kg) every 12 or 24 hours per patient’s renal function. In addition to the type and dose of anticoagulant, patients must have been initiated on the regimen within the first 72 hours of mechanical ventilation and then continued for at least 72 hours to be classified in therapeutic or prophylaxis dosing groups.

A new thromboembolic event was defined as suspected by the attending provider (without an alternative diagnosis) or confirmed via ultrasonography, computed tomography or other imaging tests. Major bleeding was defined per WHO grade 3 or 4 such as bleeding requiring red blood cell transfusion over routine transfusion needs, bleeding associated with moderate or major hemodynamic instability, fatal bleeding or a bleed involving the central nervous system on imaging study with or without dysfunction. Crossover was defined as any therapeutic anticoagulation regimen which was switched to prophylactic regimen or vice versa not due to bleeding diathesis or thromboembolism.

Study Outcomes. The primary endpoint measured was 14-day mortality. Secondary endpoints included 30-day mortality, duration of mechanical ventilation, major bleeding, and new thromboembolic event. Other pre-defined endpoints included hospital LOS.

Statistical Analysis. For comparison of categorical variables between the two groups, Fisher exact test or chi-squared test were used as appropriate. Fisher’s test was used to compare 14-day mortality, 30-day mortality, new thromboembolic event, and major bleed between the two groups. Wilcoxon sum test was used for comparison of continuous variables such as hospital LOS. P values less than 0.05 were deemed to be significant.

Results
A total of 121 mechanically ventilated adult patients with COVID-19 admitted to the ICU who received heparin or enoxaparin during the study period were identified. A total of 33 patients in the therapeutic dose group and 34 patients in the prophylaxis dose group were included in the final analysis (Figure 2). There were no statistical differences between patient age, sex, BMI, PaO2/FiO2 ratio on intubation, ferritin level, APACHE II score, and Charlson Comorbidity Index between the groups. Patients in therapeutic dose group had significantly higher d-dimer, fibrinogen, and CRP levels (Table 1).

The therapeutic anticoagulation group had a statistically significant decrease in 14-day mortality compared to the prophylaxis dose group (9.1% vs 41.2%, p=0.003). 30-day mortality was also lower in the therapeutic anticoagulation group (24.2% vs 52.9%, p=0.016). A longer duration of mechanical ventilation (39.9 vs 13.3 days, p<0.001) and hospital LOS (45.7 vs 26 days, p=0.003) was observed in patients on therapeutic anticoagulation (Table 2).

While there were decreased thromboembolic events (9% vs 17.6% p=0.476) for patients who received therapeutic anticoagulation, no statistically significant differences were observed. The most common type of thrombotic event was pulmonary embolism (PE) in the thromboprophylaxis group and deep vein thrombosis (DVT) in the therapeutic anticoagulation group (supplementary material). Of note, two of the three new thromboembolic events in the therapeutic dose group occurred after therapeutic anticoagulation was discontinued while patients were transitioned to prophylaxis dosing.
The therapeutic dose group had a higher rate of major bleeding than the prophylaxis dose group (48.5% vs 14.7%, p=0.043). The most common type of major bleeding was grade 3 bleeding requiring red blood cell transfusion over routine transfusion needs (supplementary material).

Discussion
At a regional teaching hospital in Maryland, we report a beneficial effect of therapeutic anticoagulation in reducing 14-day mortality in mechanically ventilated patients with COVID-19. To our knowledge, this is one of only a few studies to evaluate therapeutic versus prophylaxis dose anticoagulation in mechanically ventilated COVID-19 patients in the ICU. Parapanjpe et al. analyzed the effect of anticoagulation on mortality in 2,773 COVID-19 patients and reported that longer duration of therapeutic anticoagulation was associated with a reduced risk of mortality\(^1\). Recently, Trinh et al. demonstrated a marked reduction in mortality in 161 mechanically ventilated patients with COVID-19 who received therapeutic anticoagulation, suggesting that early initiation of anticoagulation after mechanical ventilation can lead to increased survival\(^1\). Our findings are consistent with the aforementioned studies, with a primary endpoint targeted at 14-day mortality. Profound mortality reduction was observed in therapeutically anticoagulated patients despite having a higher severity of disease than patients in the prophylaxis anticoagulation group. An increased length of stay and duration of mechanical ventilation in therapeutic anticoagulation group can be attributed to increased survival.

These results add to the proposed hypothesis that while mortality in COVID-19 is largely due to hypoxemia secondary to ARDS, an underlying hypercoagulable state marked by high D-dimers may be a contributing factor. Microvascular clot formation induced by vascular and endothelial injury as well as macrovascular thrombosis can result in thromboembolic sequelae leading to worsened patient outcomes\(^1\). Grasselli et al. discussed a subgroup of COVID-19 patients with ARDS characterized by low static respiratory compliance and high D-dimer concentrations who had markedly increased mortality compared to non-COVID-19 ARDS patients, suggesting additional pathophysiology leading to differences in survival\(^1\). Although D-dimer values are elevated in the majority of critically ill patients, certain thresholds for screening evaluation may be indicated. Cui et al. reported that venous thromboembolism (VTE) in patients with severe COVID-19 may be related to poor prognosis and significant increases in D-dimer in COVID-19 patients is a good index for identifying high-risk groups for VTE with a high positive predictive value (PPV)\(^1\). Our institutional ICU algorithm used a D-dimer level greater than 3000 nanograms per milliliter or an elevation of at least six times baseline as a threshold to recommend therapeutic anticoagulation. However, new thromboembolism event rates in this study were lower than reported in literature for patients receiving thromboprophylaxis, likely attributed to computed tomography (CT) angiography not available for COVID-19 patients and venous ultrasound not performed unless clinically warranted\(^1\). Therefore, microvascular and macrovascular thrombosis may remain undetected as recently reported by Nadkarni et al\(^1\).

Higher rates of major bleeding in therapeutic anticoagulation group indicate an ongoing need to review bleeding risk in individual patients and shared decision making after evaluation of benefits and risk of therapy. Of note, a decrease in 14 and 30-day mortality in therapeutic anticoagulation group was seen despite increased bleeding.

This study is not without limitations which include a retrospective single-center design and small sample size making it less generalizable to hospitals with dissimilar populations. Second, differences in availability of adequate clinician staffing and hospital resources such as personal protective equipment (PPE) and medications (including heparin and its derivatives) need to be addressed when determining the generalizability of this data to other institutions. Patients in the therapeutic anticoagulation group had a higher incidence of receiving corticosteroids, which have shown to reduce mortality in COVID-19 patients, making the results less likely due to the treatment groups alone (supplementary material). This could confound overall results. Suspected pulmonary embolisms were not confirmed by radiography due to CT angiography being difficult to obtain in COVID-19 positive patients. Prophylaxis group and therapeutic anticoagulation had a crossover rate of 38% and 27.3% respectively, which can confound overall results. Since our hospital protocol excluded patients with high bleeding risk per HAS-BLED score > 3 or provider preference, potential benefit of therapeutic anticoagulation cannot be extrapolated to that population. Lastly, our decision to exclude patients who were on mechanical ventilation for less than 72 hours introduces immortal time bias. However, we believe those patients did not receive an appropriate duration or consistency of anticoagulation with achievement of goal therapeutic ranges to be definitely considered in either group.

Conclusion
In conclusion, therapeutic dose anticoagulation was associated with decreased 14-day and 30-day mortality in mechanically ventilated ICU patients with COVID-19. Due to the increase in major bleeding, risks versus benefits of therapeutic anticoagulation should be weighed in individual cases to assist in clinical decision making. Prospective, multicenter, randomized-controlled trials are needed to determine whether systemic anticoagulation results in a survival benefit in mechanically ventilated patients with COVID-19.
Acknowledgments: The authors would like to acknowledge Drs. Barry Meisenberg and George Samaras for encouraging research at our institution, in addition to the Luminis Health COVID Clinical Management Committee for incredible collaboration in the midst of the COVID-19 pandemic. In addition, the authors acknowledge Jamie Caldwell and Doug Hosie for providing pharmacy administrative support. Lastly, the authors thank Robert Freeman, Ph.D. for reviewing the statistical analysis within this study.

Conflicts of Interest: The authors have declared no potential conflicts of interest.

Treatment of Human Subjects: IRB review/approval required and obtained

References


Table 1. Baseline patient demographics and clinical scores

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Prophylactic <em>n=34</em></th>
<th>Therapeutic <em>n=33</em></th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>66 (55.3 - 73.3)</td>
<td>59.7 (50.5 - 68)</td>
<td>0.144</td>
</tr>
<tr>
<td>Male sex, n (%)</td>
<td>17 (50%)</td>
<td>19 (57.6%)</td>
<td>0.627</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>32.5 (26.2 - 37.3)</td>
<td>30 (24.1 - 36.9)</td>
<td>0.195</td>
</tr>
<tr>
<td>Charlson Comorbidity Index</td>
<td>4 (3 – 5)</td>
<td>3 (1.5 – 3.5)</td>
<td>0.11</td>
</tr>
<tr>
<td>APACHE II Score</td>
<td>24 (19 - 28.3)</td>
<td>23 (18 - 28)</td>
<td>0.496</td>
</tr>
<tr>
<td>HAS-BLED Score</td>
<td>2.5 (1 - 3)</td>
<td>1 (0 - 2)</td>
<td>0.002</td>
</tr>
<tr>
<td>CRP, mg/L</td>
<td>11.9 (6.76 - 17.9)</td>
<td>18.4 (11.9 - 19)</td>
<td>0.014</td>
</tr>
<tr>
<td>D-dimer, mcg/mL</td>
<td>2.55 (1.28 – 3.65)</td>
<td>5.47 (3.42 - 20)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fibrinogen, mg/dL</td>
<td>615 (519 – 745)</td>
<td>786.3 (620 - 973)</td>
<td>0.022</td>
</tr>
<tr>
<td>Ferritin, ng/mL</td>
<td>742 (370 - 1357)</td>
<td>1199 (623 - 2406)</td>
<td>0.41</td>
</tr>
<tr>
<td>PaO2/FiO2 ratio</td>
<td>118 (71 - 154)</td>
<td>77 (62.5 - 125.5)</td>
<td>0.09</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, Body Mass Index; CRP, C-Reactive Protein.

aData are presented as median (IQR), unless specified otherwise.

Table 2. Primary, secondary, and other pre-defined endpoints

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Prophylactic <em>(n=34)</em></th>
<th>Therapeutic <em>(n=33)</em></th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary</td>
<td>14-day mortality</td>
<td>14 (41.2)</td>
<td>3 (9.1)</td>
</tr>
<tr>
<td>Secondary</td>
<td>30-day mortality</td>
<td>18 (52.9)</td>
<td>8 (24.2)</td>
</tr>
<tr>
<td>Duration of mechanical ventilation, days, mean (± SD)</td>
<td>13.3 (± 11.9)</td>
<td>33.9 (± 20.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>New thromboembolism, events (%)</td>
<td>6 (17.6)</td>
<td>3 (9.1)</td>
<td>0.476</td>
</tr>
<tr>
<td>Major bleed, events (%)</td>
<td>7 (20.6)</td>
<td>22 (66.7)</td>
<td>0.043</td>
</tr>
<tr>
<td>Pre-specified</td>
<td>Hospital LOS, mean (± SD)</td>
<td>26 (± 17.2)</td>
<td>45.7 (± 19.2)</td>
</tr>
</tbody>
</table>

aData are presented number (percent) of patients, unless specified otherwise.
Figure 1. Institutional anticoagulation algorithm to guide clinical decision making regarding thromboprophylaxis or therapeutic anticoagulation in the ICU.

D-dimer > 3000 ng/mL or > 6x from baseline?

Y E S

N O

Patient with AKI, ESRD, or on RRT?

Y E S

Therapeutic Anticoagulation

N O

Patient with AKI, ESRD, or on RRT?

ICU
- Heparin IV infusion per pharmacy protocol

ICU
- CrCl < 30 ml/min: Enoxaparin 1 mg/kg subcutaneous BID
- CrCl < 30 ml/min: Enoxaparin 1 mg/kg subcutaneous daily

ICU
- High Dose Thromboprophylaxis:
  - Heparin 7500 units subcutaneous q 8 hours

ICU
- High Dose Thromboprophylaxis:
  - CrCl > 30 ml/min: Enoxaparin 40 mg subcutaneous BID
  - CrCl < 30 ml/min: Heparin 7500 units subcutaneous q 8 hours

Patient Selection
- Inclusion: All patients admitted with COVID-19
- Exclusion: high risk of bleeding (clinical judgement, HASBLED > 3), contraindication to anticoagulation, HIT, weight < 50 kg, or pregnancy

Contraindications to therapeutic anticoagulation
- Platelet count < 50,000 (consider discontinuation of thromboprophylaxis with platelet count < 25,000)
- INR > 1.5
- Fibrinogen < 100 mg/dl (consider discontinuation of thromboprophylaxis with fibrinogen < 50 mg/dl)
- Active or recent bleeding diathesis (consider discontinuation of thromboprophylaxis)

Recommended labs for therapeutic anticoagulation
- CBC daily
- D-Dimer every 48 hours
- Fibrinogen every 48 hours

References
Figure 2. Selection flowchart of study patients.

**Evaluated**
121 COVID-19 mechanically ventilated ICU patients who received heparin/enoxaparin

**Excluded:** 54 patients
- < 72 hours on Mechanical Ventilation (25)
- New onset atrial fibrillation (1)
- Prior to admit anticoagulant (20)
- Transferred in/out (7)
- Pregnancy/peripartum (1)

**Prophylactic Anticoagulation**
- 34 patients

**Therapeutic Anticoagulation**
- 33 patients